IRESSA™ (Gefitinib) in Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: gefitinib (IRESSA™, ZD1839)
Sponsor: AstraZeneca